Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.20
CHE's Cash to Debt is ranked lower than
57% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 0.30 vs. CHE: 0.20 )
Ranked among companies with meaningful Cash to Debt only.
CHE' s 10-Year Cash to Debt Range
Min: 0.01  Med: 0.20 Max: 2.78
Current: 0.2
0.01
2.78
Equity to Asset 0.54
CHE's Equity to Asset is ranked higher than
67% of the 207 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. CHE: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
CHE' s 10-Year Equity to Asset Range
Min: 0.36  Med: 0.52 Max: 0.61
Current: 0.54
0.36
0.61
Interest Coverage 20.50
CHE's Interest Coverage is ranked higher than
67% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: 6.48 vs. CHE: 20.50 )
Ranked among companies with meaningful Interest Coverage only.
CHE' s 10-Year Interest Coverage Range
Min: 1.85  Med: 4.34 Max: 20.5
Current: 20.5
1.85
20.5
F-Score: 9
Z-Score: 7.22
M-Score: -2.38
WACC vs ROIC
7.06%
18.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.72
CHE's Operating margin (%) is ranked higher than
65% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 7.11 vs. CHE: 11.72 )
Ranked among companies with meaningful Operating margin (%) only.
CHE' s 10-Year Operating margin (%) Range
Min: -2.6  Med: 8.34 Max: 11.56
Current: 11.72
-2.6
11.56
Net-margin (%) 7.08
CHE's Net-margin (%) is ranked higher than
69% of the 217 Companies
in the Global Medical Care industry.

( Industry Median: 3.47 vs. CHE: 7.08 )
Ranked among companies with meaningful Net-margin (%) only.
CHE' s 10-Year Net-margin (%) Range
Min: -3.61  Med: 5.63 Max: 10.72
Current: 7.08
-3.61
10.72
ROE (%) 23.20
CHE's ROE (%) is ranked higher than
88% of the 201 Companies
in the Global Medical Care industry.

( Industry Median: 8.83 vs. CHE: 23.20 )
Ranked among companies with meaningful ROE (%) only.
CHE' s 10-Year ROE (%) Range
Min: -5.58  Med: 13.59 Max: 22.06
Current: 23.2
-5.58
22.06
ROA (%) 12.17
CHE's ROA (%) is ranked higher than
89% of the 219 Companies
in the Global Medical Care industry.

( Industry Median: 3.60 vs. CHE: 12.17 )
Ranked among companies with meaningful ROA (%) only.
CHE' s 10-Year ROA (%) Range
Min: -2.96  Med: 6.21 Max: 11.33
Current: 12.17
-2.96
11.33
ROC (Joel Greenblatt) (%) 165.85
CHE's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 15.83 vs. CHE: 165.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CHE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5.42  Med: 150.21 Max: 228.57
Current: 165.85
-5.42
228.57
Revenue Growth (3Y)(%) 8.00
CHE's Revenue Growth (3Y)(%) is ranked higher than
51% of the 158 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. CHE: 8.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CHE' s 10-Year Revenue Growth (3Y)(%) Range
Min: -18.9  Med: 11.00 Max: 42.9
Current: 8
-18.9
42.9
EBITDA Growth (3Y)(%) 9.20
CHE's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 123 Companies
in the Global Medical Care industry.

( Industry Median: 7.60 vs. CHE: 9.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CHE' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -31.3  Med: 9.80 Max: 52.3
Current: 9.2
-31.3
52.3
EPS Growth (3Y)(%) 10.80
CHE's EPS Growth (3Y)(%) is ranked higher than
54% of the 116 Companies
in the Global Medical Care industry.

( Industry Median: 9.00 vs. CHE: 10.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CHE' s 10-Year EPS Growth (3Y)(%) Range
Min: -15.4  Med: 11.90 Max: 56.8
Current: 10.8
-15.4
56.8
» CHE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CHE Guru Trades in Q3 2014

Ken Fisher 530,910 sh (New)
Jim Simons 89,800 sh (+9.38%)
John Keeley 21,400 sh (unchged)
Richard Pzena Sold Out
Mario Gabelli 793,833 sh (-4.98%)
Joel Greenblatt 159,963 sh (-20.46%)
John Hussman 84,000 sh (-32.80%)
Chuck Royce 746,776 sh (-42.85%)
» More
Q4 2014

CHE Guru Trades in Q4 2014

Jim Simons 105,800 sh (+17.82%)
Ken Fisher 570,040 sh (+7.37%)
John Hussman 84,000 sh (unchged)
Chuck Royce 481,654 sh (unchged)
Chuck Royce 481,654 sh (unchged)
John Keeley 20,600 sh (-3.74%)
Mario Gabelli 748,686 sh (-5.69%)
Chuck Royce 362,654 sh (-51.44%)
Joel Greenblatt 32,701 sh (-79.56%)
» More
Q1 2015

CHE Guru Trades in Q1 2015

Jim Simons 119,000 sh (+12.48%)
Joel Greenblatt 35,185 sh (+7.60%)
Ken Fisher 585,435 sh (+2.70%)
John Keeley 20,200 sh (-1.94%)
Chuck Royce 351,988 sh (-2.94%)
Mario Gabelli 720,693 sh (-3.74%)
John Hussman 79,000 sh (-5.95%)
» More
Q2 2015

CHE Guru Trades in Q2 2015

John Keeley 20,390 sh (+0.94%)
Ken Fisher 575,585 sh (-1.68%)
Mario Gabelli 701,919 sh (-2.60%)
Chuck Royce 294,497 sh (-16.33%)
John Hussman 65,000 sh (-17.72%)
Jim Simons 33,300 sh (-72.02%)
Joel Greenblatt 3,617 sh (-89.72%)
» More
» Details

Insider Trades

Latest Guru Trades with CHE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Chemed Corp

Mario Gabelli Comments on Chemed Corp. - Jan 29, 2014

Chemed Corp. (CHE)(0.3%) (CHE - $76.62 - NYSE) , based in Cincinnati, OH, is a holding company that owns the Vitas hospice company and the Roto Rooter plumbing business. Vitas is the nation's largest hospice company, with almost $1 billion in annual sales. The company is currently facing headwinds from government billing changes and a regulatory investigation, but its management is working hard to protect margins and it should begin to move beyond these issues in 2014. Roto Rooter is enjoying steady revenue growth and record profitability as the economy, particularly the housing market, improves. With strong free cash flow and modest capital expenditures, Chemed is returning the vast majority of its cash flow to shareholders via significant share repurchases.

 

From Mario Gabelli (Trades, Portfolio)’s Gabelli Asset Fund fourth quarter 2013 commentary.

Check out Mario Gabelli latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 23.02
CHE's P/E(ttm) is ranked higher than
59% of the 151 Companies
in the Global Medical Care industry.

( Industry Median: 26.50 vs. CHE: 23.02 )
Ranked among companies with meaningful P/E(ttm) only.
CHE' s 10-Year P/E(ttm) Range
Min: 10.7  Med: 18.08 Max: 41.64
Current: 23.02
10.7
41.64
Forward P/E 19.31
CHE's Forward P/E is ranked higher than
51% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 19.76 vs. CHE: 19.31 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.50
CHE's PE(NRI) is ranked higher than
59% of the 149 Companies
in the Global Medical Care industry.

( Industry Median: 27.90 vs. CHE: 23.50 )
Ranked among companies with meaningful PE(NRI) only.
CHE' s 10-Year PE(NRI) Range
Min: 10.72  Med: 17.79 Max: 52.26
Current: 23.5
10.72
52.26
P/B 4.92
CHE's P/B is ranked lower than
81% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: 2.62 vs. CHE: 4.92 )
Ranked among companies with meaningful P/B only.
CHE' s 10-Year P/B Range
Min: 1.89  Med: 2.81 Max: 5.39
Current: 4.92
1.89
5.39
P/S 1.62
CHE's P/S is ranked lower than
55% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. CHE: 1.62 )
Ranked among companies with meaningful P/S only.
CHE' s 10-Year P/S Range
Min: 0.67  Med: 1.05 Max: 1.78
Current: 1.62
0.67
1.78
PFCF 26.35
CHE's PFCF is ranked lower than
58% of the 117 Companies
in the Global Medical Care industry.

( Industry Median: 24.04 vs. CHE: 26.35 )
Ranked among companies with meaningful PFCF only.
CHE' s 10-Year PFCF Range
Min: 7.11  Med: 13.32 Max: 81.56
Current: 26.35
7.11
81.56
POCF 17.96
CHE's POCF is ranked lower than
61% of the 158 Companies
in the Global Medical Care industry.

( Industry Median: 15.33 vs. CHE: 17.96 )
Ranked among companies with meaningful POCF only.
CHE' s 10-Year POCF Range
Min: 5.92  Med: 10.22 Max: 29.68
Current: 17.96
5.92
29.68
EV-to-EBIT 13.98
CHE's EV-to-EBIT is ranked higher than
72% of the 170 Companies
in the Global Medical Care industry.

( Industry Median: 19.71 vs. CHE: 13.98 )
Ranked among companies with meaningful EV-to-EBIT only.
CHE' s 10-Year EV-to-EBIT Range
Min: 6.9  Med: 10.80 Max: 24.5
Current: 13.98
6.9
24.5
PEG 2.53
CHE's PEG is ranked higher than
58% of the 69 Companies
in the Global Medical Care industry.

( Industry Median: 2.77 vs. CHE: 2.53 )
Ranked among companies with meaningful PEG only.
CHE' s 10-Year PEG Range
Min: 0.31  Med: 1.21 Max: 5.41
Current: 2.53
0.31
5.41
Shiller P/E 30.10
CHE's Shiller P/E is ranked higher than
50% of the 86 Companies
in the Global Medical Care industry.

( Industry Median: 30.72 vs. CHE: 30.10 )
Ranked among companies with meaningful Shiller P/E only.
CHE' s 10-Year Shiller P/E Range
Min: 15.74  Med: 24.24 Max: 137.8
Current: 30.1
15.74
137.8
Current Ratio 1.17
CHE's Current Ratio is ranked lower than
56% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. CHE: 1.17 )
Ranked among companies with meaningful Current Ratio only.
CHE' s 10-Year Current Ratio Range
Min: 0.57  Med: 1.21 Max: 1.88
Current: 1.17
0.57
1.88
Quick Ratio 1.14
CHE's Quick Ratio is ranked lower than
53% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. CHE: 1.14 )
Ranked among companies with meaningful Quick Ratio only.
CHE' s 10-Year Quick Ratio Range
Min: 0.56  Med: 1.12 Max: 1.79
Current: 1.14
0.56
1.79
Days Inventory 2.19
CHE's Days Inventory is ranked higher than
90% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 17.13 vs. CHE: 2.19 )
Ranked among companies with meaningful Days Inventory only.
CHE' s 10-Year Days Inventory Range
Min: 2.27  Med: 3.83 Max: 68.23
Current: 2.19
2.27
68.23
Days Sales Outstanding 29.06
CHE's Days Sales Outstanding is ranked higher than
75% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 46.03 vs. CHE: 29.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHE' s 10-Year Days Sales Outstanding Range
Min: 16.34  Med: 32.17 Max: 56.06
Current: 29.06
16.34
56.06

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.65
CHE's Dividend Yield is ranked lower than
87% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 1.80 vs. CHE: 0.65 )
Ranked among companies with meaningful Dividend Yield only.
CHE' s 10-Year Dividend Yield Range
Min: 0.35  Med: 0.74 Max: 1.2
Current: 0.65
0.35
1.2
Dividend Payout 0.15
CHE's Dividend Payout is ranked higher than
93% of the 132 Companies
in the Global Medical Care industry.

( Industry Median: 0.46 vs. CHE: 0.15 )
Ranked among companies with meaningful Dividend Payout only.
CHE' s 10-Year Dividend Payout Range
Min: 0.07  Med: 0.17 Max: 11
Current: 0.15
0.07
11
Dividend growth (3y) 11.90
CHE's Dividend growth (3y) is ranked higher than
52% of the 67 Companies
in the Global Medical Care industry.

( Industry Median: 11.90 vs. CHE: 11.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
CHE' s 10-Year Dividend growth (3y) Range
Min: -42.4  Med: 2.20 Max: 35.7
Current: 11.9
-42.4
35.7
Yield on cost (5-Year) 1.43
CHE's Yield on cost (5-Year) is ranked lower than
68% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 2.12 vs. CHE: 1.43 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
CHE' s 10-Year Yield on cost (5-Year) Range
Min: 0.77  Med: 1.62 Max: 2.63
Current: 1.43
0.77
2.63
Share Buyback Rate 5.20
CHE's Share Buyback Rate is ranked higher than
98% of the 125 Companies
in the Global Medical Care industry.

( Industry Median: -2.20 vs. CHE: 5.20 )
Ranked among companies with meaningful Share Buyback Rate only.
CHE' s 10-Year Share Buyback Rate Range
Min: 6.9  Med: 1.30 Max: -10.2
Current: 5.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.34
CHE's Price/Projected FCF is ranked higher than
57% of the 100 Companies
in the Global Medical Care industry.

( Industry Median: 1.53 vs. CHE: 1.34 )
Ranked among companies with meaningful Price/Projected FCF only.
CHE' s 10-Year Price/Projected FCF Range
Min: 0.59  Med: 1.24 Max: 2.33
Current: 1.34
0.59
2.33
Price/DCF (Earnings Based) 0.97
CHE's Price/DCF (Earnings Based) is ranked higher than
83% of the 23 Companies
in the Global Medical Care industry.

( Industry Median: 1.49 vs. CHE: 0.97 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.54
CHE's Price/Median PS Value is ranked lower than
80% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 1.11 vs. CHE: 1.54 )
Ranked among companies with meaningful Price/Median PS Value only.
CHE' s 10-Year Price/Median PS Value Range
Min: 0.48  Med: 0.92 Max: 1.67
Current: 1.54
0.48
1.67
Price/Peter Lynch Fair Value 2.42
CHE's Price/Peter Lynch Fair Value is ranked higher than
51% of the 53 Companies
in the Global Medical Care industry.

( Industry Median: 2.47 vs. CHE: 2.42 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CHE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.51  Med: 1.35 Max: 5.14
Current: 2.42
0.51
5.14
Earnings Yield (Greenblatt) (%) 7.14
CHE's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 4.20 vs. CHE: 7.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CHE' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4.1  Med: 9.20 Max: 14.5
Current: 7.14
4.1
14.5
Forward Rate of Return (Yacktman) (%) 13.37
CHE's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 104 Companies
in the Global Medical Care industry.

( Industry Median: 11.17 vs. CHE: 13.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CHE' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -13.4  Med: 19.30 Max: 60.1
Current: 13.37
-13.4
60.1

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 1,525 1,584
EPS($) 6.59 7.18
EPS without NRI($) 6.59 7.18

Business Description

Industry: Health Care Providers » Medical Care
Compare:FMS, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:CXM.Germany,
Chemed Corp was incorporated in Delaware in 1970. The Company conducts its business operations in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). VITAS Healthcare Corporation provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. Roto-Rooter provides plumbing and drain cleaning services to both residential and commercial customers. Roto-Rooter has manufacturing and distribution center facilities in West Des Moines, Iowa and has 109 leased and owned office and service facilities in 30 states. VITAS operate 51 programs from 154 leased facilities and 37 inpatient units in 18 states and the District of Columbia. The Company faces competition from sewer, drain and pipe cleaning, excavation and plumbing repair businesses and is fragmented, with the bulk of the industries consisting of local and regional competitors. VITAS competes with a number of national and regional hospice providers, including Gentiva Health Services, Inc., hospitals, nursing homes, home health agencies and other health care providers. The Company is subject to federal, state and local laws and regulations relating to franchising, insurance and other aspects of business.
» More Articles for CHE

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Chemed Corp. Jan 29 2014 
The Gabelli Asset Fund Shareholder Commentary - Fourth Quarter 2013 Jan 29 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
comment on CHE May 07 2013 
comment on CHE May 07 2013 
Chemed Corporation: Fundamental Stock Research Analysis Jan 29 2013 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
hospice, roto rooter Jan 11 2012 
9 Dividend Stocks Raising Their Yield On Cost Aug 15 2011 
Guru Stocks Raising Dividends: THO, ACU, KAMN, PRIM, CHE Aug 15 2011 

More From Other Websites
Chemed Corp. Earnings Q2, 2015 Aug 27 2015
CK Hutchison Highlights of the Unaudited Results for the six months ended 30 June 2015 Aug 25 2015
A.S. Watson Group Opens its 12,000th Store Worldwide in Hong Kong Aug 11 2015
CHEMED CORP Financials Aug 07 2015
Chemed Corporation Increases Quarterly Dividend Aug 07 2015
Chemed Corporation Increases Quarterly Dividend Aug 07 2015
CK Hutchison and VimpelCom to form joint venture of their telecoms businesses in Italy Aug 06 2015
HTHKH Unaudited Results for the Six Months Ended 30 June 2015 Aug 04 2015
How to Uncover Institutional Buying - Screen of the Week Aug 04 2015
10-Q for Chemed Corp. Aug 03 2015
Why Chemed Corp. (CHE) Stock Might be a Great Pick - Tale of the Tape Jul 31 2015
CHEMED CORP Files SEC form 10-Q, Quarterly Report Jul 31 2015
UNLOCKED: Cincinnati CEOs haul in perks Jul 29 2015
Husky Energy delivers steady progress in second quarter Jul 28 2015
Husky Energy announces 2015 second quarter dividends Jul 28 2015
Chemed Tops Q2 Earnings on Strong Revenues, Guides Up - Analyst Blog Jul 28 2015
Edited Transcript of CHE earnings conference call or presentation 24-Jul-15 2:00pm GMT Jul 27 2015
Chemed Corp Earnings Call scheduled for 10:00 am ET today Jul 24 2015
Chemed posts 2Q profit Jul 23 2015
Chemed posts 2Q profit Jul 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK